Relative dose intensity of R‐CHOP therapy and patient outcomes in advanced follicular lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Relative dose intensity of R‐CHOP therapy and patient outcomes in advanced follicular lymphoma

Published:2019-04-26 Issue:3 Volume:37 Page:303-307
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Konishi Tatsuya¹²^ORCID,Kanemasa Yusuke¹^ORCID,Sasaki Yuki³,Okuya Toshihiro¹,Yamaguchi Tsukasa¹,Funasaka Chikako¹,Shimoyama Tatsu¹,Omuro Yasushi¹

Affiliation:

1. Department of Medical OncologyTokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

2. Hematology DivisionTokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

3. Department of Clinical ResearchTokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2614

Reference14 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

2. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

3. Follicular lymphoma: evolving therapeutic strategies

4. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome

5. Management of untreated advanced stage follicular lymphoma: Role of patient discernment

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma;Annals of Hematology;2022-11-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3